GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Fixed Maturity Investment

Transgene (XPAR:TNG) Fixed Maturity Investment


View and export this data going back to 1998. Start your Free Trial

What is Transgene Fixed Maturity Investment?

Fixed Maturity Investment only applies to insurance companies.


Transgene Business Description

Industry
Traded in Other Exchanges
Address
400 Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, FRA, 67400
Transgene SA is a biotechnology company. The Company conducts its business exclusively in the clinical research and development of therapeutic vaccines and immunotherapeutic products. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products. The majority of its operations is located in France.